Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

The Maharashtra Food and Drug Administration (FDA) recently banned the sale, distribution, and use of several fairness creams after dangerous levels of toxic heavy metals, including lead and mercury, were found in the products.

About The Case

Among the products, one named Goree Beauty Cream is of Pakistani origin. The product was reportedly being sold unlawfully in the state.

The FDA labelled the products “Not of Standard Quality” (NSQ), warning consumers against using them as prolonged exposure to heavy metals present in the products can lead to serious health complications associated with skin, kidneys as well as the nervous system.

According to the Maharashtra FDA, the following cosmetic products have been declared unsafe:

1. Goree Beauty Cream
2. Face Fresh Gold
3. Golden Star Beauty Cream

Officials also noted that the products lacked mandatory information like the manufacturer's complete details, batch number, manufacturing date, and expiry date, raising concerns over their authenticity and safety.

Also read: Bryan Johnson Blames Sugary Cereals, Soda and Stress for His Autoimmune Disease; Shares Treatment Plan

What Happens When One Gets Exposed To Lead And Mercury?

If used repeatedly, these toxic substances may be absorbed through the skin, allowing them to accumulate in the body over time.

Excessive exposure to mercury can cause:

• Kidney damage

• Tremors and muscle weakness

• Numbness or tingling sensations

• Memory problems and difficulty concentrating

• Mood changes and irritability

• Skin rashes and discoloration

• Harm to unborn babies during pregnancy

The risk increases with prolonged use, particularly when the products are used on a daily basis over months or years.

Also read: Australia Reports More H5 Bird Flu Cases: Does It Have Pandemic Potential?

On the other hand, lead exposure can cause:

• Damage to the nervous system

• High blood pressure

• Kidney dysfunction

• Fertility problems

• Developmental delays in children

• Pregnancy complications

Even if lead accumulates in the body in small amounts, its repeated use may pose long-term health risks.

Why Are Lead And Mercury Found In Fairness Creams?

Sometimes, mercury is illegally added to skin-lightening products as it suppresses melanin production, temporarily making the skin appear lighter. However, this skin-lightening effect comes at the cost of significant health risks.

Lead may contaminate cosmetic products through poor-quality raw materials or unsafe manufacturing processes. Neither ingredient should be intentionally present in cosmetic creams sold for routine use.

International health agencies have repeatedly warned against skin-lightening creams containing mercury.

In June 2026, the US FDA again cautioned consumers not to use over-the-counter skin-lightening products found to contain mercury or hydroquinone because of the risk of kidney injury, neurological damage, and permanent skin problems.

The Maharashtra FDA's crackdown highlights the hidden dangers of unregulated and illegal fairness creams that contain harmful ingredients.

While these products may promise lighter skin, the presence of toxic heavy metals such as mercury and lead can expose users to potentially irreversible health damage. Consumers are advised to read the labels carefully before purchasing any skincare products that promise complexion-altering effects.

Usually, the most telling symptoms of Alzheimer's disease surface in old age. With no cure and limited ways to detect it early, it is challenging to treat and manage Alzheimer's. However, a recent study says that a new blood test can help in diagnosing Alzheimer's early.

New Blood Test May Predict Alzheimer's Symptoms Early

A new blood test that measures tiny loops of genetic material in the bloodstream may be able to predict when Alzheimer's disease symptoms are likely to appear, offering hope for earlier intervention of the neurodegenerative disease and more effective clinical trials.

A study funded by the U.S. National Institutes of Health (NIH) says that a specific group of blood-based biomarkers known as circular RNAs could help identify people who are on the brink of developing Alzheimer's symptoms, even before memory loss or cognitive decline becomes apparent.

An Improvement On Current Blood Tests

The current blood tests for Alzheimer's have been made after significant progress in recent years, particularly by detecting proteins linked to amyloid plaques, one of the disease's primary characteristics features.

However, these tests may present positive results for many years, even decades, before symptoms like declining memory and thinking appear. It makes it difficult for doctors to predict when the disease will actually begin affecting the patient’s quality of life.

The newly developed blood test could fill that existing gap. Scientists found that elevated levels of a set of 34 circular RNAs in blood were strongly associated with future symptoms of the onset.

According to the study, those with higher circRNA levels were nearly three times more likely to develop Alzheimer's symptoms compared with those with lower levels.

The changes appeared approximately two to four years before symptoms emerged, making them a valuable diagnostic test for predicting disease progression.

Read more: WHO Issues Alert After Fake Cancer Drug Found In Maldives & Mexico; Are Counterfeit Medicines A Global Threat?

How Can This Blood Test Help?

Improve Clinical Testing

The discovery could transform existing Alzheimer's research by helping scientists identify participants who are most likely to develop symptoms during a clinical trial.

Finding out when symptoms are likely to begin would allow researchers to introduce preventive therapies at the stage when they are most likely to be effective and better evaluate whether experimental treatments can delay cognitive decline.

Less Invasive Alternative

The current methods to assess Alzheimer's include PET brain scans, which are expensive and not widely available. Lumbar punctures (spinal taps), an invasive method, is also used.

Compared to the existing methods to screen Alzheimer's, a blood test is easier to perform, less invasive, more affordable and more accessible, especially if validated for widespread clinical use.

Earlier Planning For Patients And Families

If doctors can ascertain the symptoms early, patients and their families can, patients’ families can plan future care and support. They can use the time to make financial and legal decisions while the person is still cognitively healthy. Patients can also adopt lifestyle changes that may help maintain brain health.

Researchers however stressed that the new circRNA test is still in the research stage and requires further validation in larger and more diverse populations before it can be adopted in clinical practice.

The World Health Organization (WHO) has issued a global medical product alert after identifying falsified batches of the cancer medicine DARZALEX (daratumumab). It also issued a warning that the counterfeit products could cause serious health risks to patients and disrupt the treatment process.

WHO Warns Against Fake Cancer Drugs

The WHO issued an alert against the circulation of falsified DARZALEX (daratumumab). The incident came to light in May and June 2026. According to the WHO, the falsified injections were found in the Maldives and Mexico after being supplied by unauthorised distributors.

In at least one reported case, hospitals received fake medication, prompting international concern over gaps in the pharmaceutical supply chain.

About The Cancer Medicine

DARZALEX (daratumumab) is an antibody that is used to treat multiple myeloma, cancer of plasma cells in the bone marrow, as well as amyloid light-chain (AL) amyloidosis, a rare blood disorder.

The drug plays a crucial role in the treatment of various types of cancer. That is why the WHO said that the circulation of its compromised version could cause delayed therapy, treatment failure, and potentially life-threatening consequences.

Read more: Why Sustainable Weight Loss Requires More Than Cutting Calories

WHO Identified The Counterfeit Batch Numbers

WHO said the fake products deliberately misrepresent their identity, composition, or source. The manufacturer, Janssen, confirmed that the batch numbers MYS7381 and STV1K01 are not valid, and any DARZALEX product bearing these batch numbers should be considered falsified and must not be used.

The Maldives Food and Drug Authority also reported visible particulate matter inside vials from one of the counterfeit batches.

The UN health agency has urged national regulatory health bodies, healthcare providers, wholesalers, and distributors to strengthen security across the pharmaceutical supply chains to prevent the infiltration of counterfeits.

It also advised countries to closely monitor unregulated pharmaceutical markets, where counterfeit medicines are more likely to circulate.

Read more: ICMR & IIT Bombay Create Placenta-On-Chip To Study Pregnancy Disorders & Drug Safety

WHO issued precautionary measures to avoid purchasing falsified medications:

• Healthcare professionals should report suspected falsified products, unexpected side effects, or lack of therapeutic effects to their national regulatory authorities and health and disease bodies.

• WHO has advised patients and caregivers to obtain medicines only from licensed pharmacies and authorised healthcare providers.

• Patients must also inspect packaging carefully and seek medical advice if they notice any unusual appearance or suspect their medication may not be genuine.

• The global health organisation stressed that people should not use any product suspected to be falsified and should report it to health authorities immediately.

Falsified Drugs Are A Growing Global Threat

The latest warning adds to a growing list of WHO medical product alerts involving counterfeit cancer medicines.

In recent years, the WHO has issued alerts for various falsified cancer drugs including IMFINZI (durvalumab), IBRANCE (palbociclib) and DEFITELIO (defibrotide), highlighting the growing threat of counterfeit medicines that could disrupt life-saving treatment courses.

The WHO estimates that more than one in ten medical products in underdeveloped and developed countries are either substandard or falsified, making poor-quality medicines one of the world's major public health challenges.